{
    "clinical_study": {
        "@rank": "129516", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "description": "using the 0.1%  fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "using the 0.05% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness of fluorometholone combined with\n      sodium hyaluronate eye drops in the treatment of Sj\u00f6gren syndrome."
        }, 
        "brief_title": "A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sj\u00f6gren Syndrome", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Dry Eye Syndromes", 
            "Sj\u00f6gren Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca", 
                "Sjogren's Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  willing to participate in this clinical study, and signed informed consent\n\n          -  age from 18 to 70 years old,both genders are permitted\n\n          -  diagnosed as the Sj\u00f6gren syndrome\n\n          -  have the symptoms and signs of dry eye disease as below:\n\n               1. have at least 2 symptoms such as dryness,foreign body sensation ,eye\n                  strain,conjunctival congestion,secretion.The summed up score of symptoms greater\n                  than 6.\n\n               2. the score of tear-film break up time less than 5 seconds or the score of\n                  Schirmer test less than 5mm/5min.\n\n               3. the score of  corneal fluorescein staining greater than 3.\n\n                  Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "the people who suffered from the dry eye disease coused by the Sj\u00f6gren syndrome"
            }
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011776", 
            "org_study_id": "FML-001", 
            "secondary_id": "FML-001"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Corticosteroids Dry Eye Sj\u00f6gren syndrome inflammation treatment", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200031"
                }, 
                "name": "Eye & Ear Hospital of Fudan University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sj\u00f6gren Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "stain the cornea with the fluorescein; close the eye; open the eye and keep the eye open,count the seconds until the first black spot appears.", 
                "measure": "tear\u2014film breakup time", 
                "safety_issue": "Yes", 
                "time_frame": "the enrolling day,2 weeks after treatment,4 weeks after treatment,8 weeks after treatment"
            }, 
            {
                "description": "put the Schirmer test strip into the lower conjunctival sac; close the eye for 5 minutes; read the score of the test strip", 
                "measure": "Schirmer test I without anesthesia", 
                "safety_issue": "Yes", 
                "time_frame": "the enrolling day,2 weeks after treatment,4 weeks after treatment, 8 weeks after treatment"
            }, 
            {
                "description": "Fluorescein staining scores were measured on 0-3 point scale, in each quarter of corneal zone: 0(No staining), 1(some staining), 2(Staining in more than a half of the area), 3(Staining in the whole area).", 
                "measure": "corneal fluorescein staining", 
                "safety_issue": "Yes", 
                "time_frame": "the enrolling day,2 weeks after treatment,4 weeks after treatment,8 weeks after treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011776"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Santen Pharmaceutical(China) Co.,LTD", 
            "investigator_full_name": "Lan Gong", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Santen Pharmaceutical(China) Co.,LTD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santen Pharmaceutical(China) Co.,LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "8 Weeks", 
        "verification_date": "December 2013"
    }
}